J&J Divests Laminar Assets Following Heart Device Trial Suspension

Key Facts

1Johnson & Johnson is selling the assets of Laminar, a company it acquired in 2023 for $400 million.

2Pivotal trials for Laminar's left atrial appendage closure device were suspended due to safety concerns.

In a move reflecting the high-stakes challenges within the medical technology sector, Johnson & Johnson has announced the sale of Laminar’s assets to a newly formed entity, Jaguar LAA. This divestment follows the suspension of pivotal trials for Laminar’s left atrial appendage closure device due to emerging safety concerns. J&J originally acquired the business in 2023 for $400 million, but the clinical setback has prompted a reallocation of resources toward higher-growth medtech segments.

Per market data, JNJ shares closed at $267.2 on September 15, 2026, trading within a daily range of $260.68 to $267.2. The decision to divest aligns with J&J's broader strategy to streamline its portfolio and focus on cardiovascular care and robotic surgery. The clinical trial, which began in early 2024 to evaluate the technology against established competitors, was halted before achieving its regulatory milestones, leading to this strategic exit.

Traders should watch for price stability around the $267.2 level (close of September 15, 2026). While the upcoming economic calendar does not feature immediate healthcare-specific catalysts for the next seven days, the market will focus on how this R&D setback impacts J&J’s long-term medtech growth trajectory and future cardiovascular product pipeline.